If the page does not redirect, click here
Phase 2b trial results of novel TB regimen show potential to shorten treatment
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.